ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Beginning Again: Living with the Ups and Downs of Life with Chronic Illness

Chronic Christmas: Surviving the Holidays with a Chronic Illness

Productivity Values That Get in the Way of Our Health

Happiness, Gratitude and Appreciation

10 Questions to Ask Yourself Before Saying Yes

The “Starvation” Disease? Metabolomics Meets Chronic Fatigue Syndrome Down Under

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

The IACFS/ME 2016 Conference Overviews #1: Energy and Exercise To the Fore

Is Chronic Fatigue Syndrome An Inflammatory Disease? The 2016 IACFS/ME Conference Overviews Pt II

Psychotherapy for ME/CFS Does Not Help Fatigue (much)

 
Print Page
Email Article

Cymbalta vs. Lyrica: Medical Costs and Medication Compliance Among Fibromyalgia Patients

  [ 3 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 26, 2013


Editor's Note: This study compares both total medical costs and medication compliance among fibromyalgia patients who began taking either duloxetine (Cymbalta) or pregabalin (Lyrica) during the year 2008.  At that time, milnacipran (Savella) had not yet been approved for treating FM. 

Direct Medical Costs and Medication Compliance among Fibromyalgia Patients: Duloxetine Initiators vs. Pregabalin Initiators.
– Source: Pain Practice, March 14, 2013

By P. Sun, et al.

Abstract:

OBJECTIVES: To assess and compare direct medical costs and medication compliance between patients with fibromyalgia who initiated duloxetine and patients with fibromyalgia who initiated pregabalin in 2008.

METHODS:
A retrospective cohort study design was used based on a large US national commercial claims database (2006 to 2009). Patients with fibromyalgia aged 18 to 64 who initiated duloxetine or pregabalin in 2008 and who had continuous health insurance 1 year preceding and 1 year following the initiation were selected into duloxetine cohort or pregabalin cohort based on their initiated agent.

Medication compliance was measured by total supply days, medication possession ratio (MPR), and proportion of patients with MPR  ?  0.8. Direct medical costs were measured by annual costs per patient and compared between the cohorts in the year following the initiation. Propensity score stratification and bootstrapping methods were used to adjust for distribution bias, as well as cross-cohort differences in demographic, clinical and economic characteristics, and medication history prior to the initiation.

RESULTS: Both the duloxetine (n  =  3,033) and pregabalin (n  =  4,838) cohorts had a mean initiation age around 49  years, 89% were women.

During the postindex year, compared to the pregabalin cohort, the duloxetine cohort had

  • higher totally annual supply days (273.5 vs. 176.6, P  <  0.05),

  • higher MPR (0.7 vs. 0.5, P  <  0.05),

  • and more patients with MPR  ?  0.8 (45.1% vs. 29.4%, P  <  0.05).

Further, relative to pregabalin cohort, duloxetine cohort had

  • lower inpatient costs ($2,994.9 vs. $4,949.6, P  <  0.05),

  • lower outpatient costs ($8,259.6 vs. $10,312.2, P  <  0.05),

  • similar medication costs ($5,214.6 vs. $5,290.8, P  >  0.05),

  • and lower total medical costs ($16,469.1 vs. $20,552.6, P  <  0.05) in the postinitiation year.

CONCLUSIONS: In a real-world setting, patients with fibromyalgia who initiated duloxetine in 2008 had better medication compliance and consumed less inpatient, outpatient, and total medical costs than those who initiated pregabalin.


Source: Pain Practice, March 14, 2013. By P. Sun, X. Peng, S. Sun, D. Novick, D.E. Faries, J.S. Andrews, M.M. Wohlreich, and A. Wu. Kailo Research Group, Indianapolis, IN, U.S.A.





Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
Coenzyme Q10 - The Energy Maker Coenzyme Q10 - The Energy Maker
Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
Enhance Eyelashes Naturally Enhance Eyelashes Naturally
How I Found My Long-Lost Energy How I Found My Long-Lost Energy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map